Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-IBD platform study in active Crohn's disease and ulcerative colitis
2025-522001-38-00Phase 2Authorised
- Sponsor
- Mirador Therapeutics
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease and autoimmune colitis comparing MT-501, MT-201 and Placebo for MT-501 (3 arms). Planned start May 2026; status: authorised.
02
Drugs
MT-501adecatumumab
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2025-522001-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522001-38-00.